Close Menu

Breaking News

Researchers reported shared and distinct genetic contributors to systemic lupus erythematosus in individuals with African or European ancestry.

A genomic and transcriptomic analysis of melanocyte skin cells from deceased donors identified cancer-related mutations in outwardly normal skin samples.

Natera claims that several Genosity products infringe its US Patent No. 10,732,220, titled "Methods for Simultaneous Amplification of Target Loci."

The companies are currently working together to commercialize their respective products including genetic tests for type 2 diabetes and gestational diabetes risk.

The test, called CovidNudge, is a version of DnaNudge's consumer DNA test that has been reengineered for the point-of-care detection of SARS-CoV-2.

The company expects product and service revenue totaling $30.1 million, driven by higher instrument revenue, offset by declining consumables revenue.

The company has shipped more than 12 million ID Now tests across the US and more than 30 million total COVID-19 tests since March.

The firm said it expects its molecular diagnostics revenues to double year over year with orders continuing to outstrip its supply capabilities. 

The awards will support clinical validation, manufacturing, and scale up for SARS-CoV-2 viral antigen and molecular detection.

The firm said that the FDA further amended an EUA for the Aptima SARS-CoV-2 assay to include the firm's pooling protocol for symptomatic testing.

The product uses spin columns to extract high molecular weight DNA with an average length of 100 kb or more from animal and bacterial cells.

The firm will conduct genomic and transcriptomic analysis to identify predictors of response to the personalized immunotherapy TG4050.

The funding will help the San Francisco-based firm apply low-depth NGS as it builds diagnostic tests to aid therapy selection in more diverse populations.

The researchers used tumor and germline whole-genome sequencing, RNA sequencing, and methylome analysis to elucidate the molecular basis of high-risk cancers.

Based on the study results, the score could be combined with other risk factors to improve predictions of contralateral breast cancer and stratify patients.

PathoNext will run Agendia's assays in its labs using next-generation sequencing and work with HiSS, Agendia's German distributor, to offer the tests to German patients.

BioFire's test is designed to detect and differentiate between SARS-CoV-2 and other respiratory pathogens, while UMass Medical's test is only for SARS-CoV-2.

The deals give 10x Genomics control of a combined 110 patents covering in situ analysis methods that the firm says will complement its existing platforms.

Besides speeding up and increasing enrollment, the Guardant360 test identified a greater number of actionable mutations than tissue-based genotyping.

The company licensed nasopharyngeal swab and toehold switch molecular detection technologies from the Wyss Institute to develop SARS-CoV-2 diagnostics.

Researchers found ancestry-specific risk variants and developed a better polygenic risk score based on a GWAS and subsequent meta-analysis.

Last month, the court also ordered two separate patent lawsuits filed by Natera against ArcherDx this year to be consolidated into one.

The merger brings tumor profiling and liquid biopsy technologies for predicting and monitoring therapeutic response to Invitae's service offerings.

Under the agreement, Intermountain will be able to implement Kailos' PGxComplete next-generation sequencing methodology in its laboratory for pharmacogenetic testing.

The randomized, Phase II trial will test ctDNA-guided second-line adjuvant therapy for stage II and III hormone receptor-positive, HER-2 negative breast cancer.

Pages

The UK and the European Union have come to a sticking point in the negotiation of how the UK might remain involved in the Horizon Europe research program, the Guardian reports.

The New York Times reports that experts pushed during a meeting of an FDA advisory board for the agency to require more safety data from SARS-CoV-2 vaccine trials.

The Washington Post reports Moderna expects that it will have enough data on its candidate SARS-CoV-2 vaccine to submit to regulatory authorities by mid-November.

In Science this week: ANXA11 variants affect calcium homeostasis and stress granule disassembly in ALS, and more.